We engineered YUMM1.7 to express known tumor antigens via introduction of minigenes encoding the G1254V mutation in Laminin subunit alpha 4 (mLama4MHC-I), the A506T mutation in Alpha-1,3-glucosyltransferase (mAlg8MHC-I), and the N710Y mutation in Integrin beta 1 (mItgb1MHC-II) NeoAgs13,20 in various combinations: mLama4MHC-I + mItgb1MHC-II (Y1.7LI line) or mAlg8MHC-I + mItgb1MHC-II (Y1.7AI line) (Figure S1A). The gene discussed is ITGB1; the disease is neoplasm.